Enthusiasm for Once-Monthly Cabenuva Is High—But There Are Questions, Too The landmark U.S. Food and Drug Administration (FDA) approval of the first long-acting injectable HIV regimen, Cabenuva (cabotegravir/rilpivirine), in January burst open a new treatment door for many people living with HIV (PLWH). The approval signaled a move from daily pills to two shots in the butt—one for cabotegravir and the other for rilpivirine—once a month. You may be asking, though, will doctors now start switching PLWH en masse from pills to injections? The short answer is no. And not everyone will even want to make the switch, although clinicians who recently spoke with TheBody said that, at least for the people who’ve heard about Cabenuva, enthusiasm is high.